March 06, 2024

IceCure’s ProSense® Delivers 100% Tumor Reduction in Early-Stage Breast Cancer

IceCure Medical Ltd. (Nasdaq: ICCM) has announced new data from a preliminary, independent breast cancer studyshowing median tumor reduction of 100% at six and 12 months following cryoablation in women deemed inoperable for breast cancer. IceCure’s ProSense® System is a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal…. [Read More]
March 06, 2024

Ibogaine’s Breakthrough Potential in Opioid Addiction Treatment: New Hope Unfolds

Ibogaine, a potent psychedelic derived from the root of a Central African shrub, is making headlines for its potential to revolutionize the treatment of opioid addiction. Despite its legal status as a controlled substance in the United States, international research highlights ibogaine’s unique ability to not only alleviate the excruciating symptoms of detox but also… [Read More]
March 05, 2024

The top small-cap picks from UBS if the market rally continues to widen out

Despite a turbulent commencement in 2024, small-cap enterprises hold promising potential for investors, suggests UBS , in light of a broader market upturn that is anticipated to boost the sector. As it stands, the Russell 2000 Index has noted a 2% increase, while the S&P 500 has gained 6.6%. However, this pattern has reversed over the… [Read More]
March 05, 2024

Tech Giants Lead a Dip in US Stock Market After Recent Surge

After a recent surge, the US stock market took a hit, led by a decline in tech giants amidst mixed economic signals ahead of Jerome Powell’s Congressional testimony. Apple, Advanced Micro Devices, and Tesla saw notable slides due to various challenges, contributing to a broader market downturn worried about high valuations among leading tech companies…. [Read More]
March 05, 2024

NRx Awaits Topline Data in Suicidal Bipolar Depression Treatment Trial

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has reached the ‘Last Patient, Last Visit’ milestone in its Phase 2b/3 Trial of NRX-101 in suicidal treatment resistant bipolar depression. The company announced that the 74th and last evaluable patient has completed their day 42 visit. Topline data is expected by the end of the quarter. NRx’s share price… [Read More]
March 05, 2024

Breakthrough Device Designation for Quanterix’s Alzheimer’s Diagnostic

High-definition diagnostics company, Quanterix Corporation (Nasdaq: QTRX), has been granted Breakthrough Device designation by the FDA for its Simoa® phospho-Tau 217 (p-Tau 217) blood test as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). p-Tau 217 has emerged as a top-performing biomarker for Alzheimer’s pathology. “Early detection is crucial in shaping effective care strategies… [Read More]
March 04, 2024

Quoin Pharmaceuticals to Include Teen Patients in Rare Disease Clinical Trials

Clinical stage biotechnology company, Quoin Pharmaceuticals (Nasdaq: QNRX) has received FDA clearance to recruit subjects aged 14 years and older into its two ongoing clinical trials for QRX003, which is being evaluated by Quoin in two separate clinical trials for the treatment of Netherton Syndrome (NS). The company’s share price soared 120% in morning trading… [Read More]